Sarah Sammons, MD

home / authors / sarah-sammons-md

Sarah Sammons, MD, is a medical oncologist and clinical investigator in the Breast Oncology Center, and an associate director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute.

Articles

Insights on Tucatinib Regimens in HER2+ Breast Cancer Treatment

Sarah Sammons, MD

November 29th 2024

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer treatment

Advances in Treating HER2+ Breast Cancer With Brain Metastases

Sarah Sammons, MD

November 2nd 2024

Sarah Sammons, MD, discusses findings from an analysis of the DESTINY-Breast03 trial regarding trastuzumab deruxtecan vs trastuzumab emtansine in the context of HER2-positive breast cancer with brain metastases.

Continued Investigation of T-DXd Shows Promise in Breast Cancer

Sarah Sammons, MD

October 28th 2024

Sarah Sammons, MD, highlights the need for further investigation into trastuzumab deruxtecan in breast cancer treatment.

Challenges in Treating Brain Metastasis in HER2-Positive Breast Cancer

Sarah Sammons, MD

October 21st 2024

Sarah Sammons, MD, discusses some of the problems seen with brain metastasis in HER2-positive metastatic breast cancer.

A Closer Look at T-DXd in HER2-Positive Breast Cancer

Sarah Sammons, MD

September 16th 2024

Sarah Sammons, MD, provides an overview of the DESTINY-Breast03 trial.